Trial reportBMC neurology2026
Plasma choline and betaine and neurological function trajectory after acute ischemic stroke.
Trial report in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01840072 (Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCholine metabolism, which participates in various biological processes, has been implicated in the development of atherosclerosis and neurological disorders. However, it remains uncertain whether disruptions in the choline metabolism contribute to longitudinal changes in neurological function.
objectivesWe aimed to prospectively investigate the associations between circulating levels of choline and betaine and neurological function trajectory among patients with ischemic stroke.
methodsData came from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). Baseline plasma levels of choline and betaine were measured in 933 participants by ultra-high-performance LC-MS/MS. Group-based trajectory model was employed to identify distinct neurological function trajectories, as measured by NIHSS at admission, 14 days or discharge, and at 3-, 12-, and 24-month follow-up.
resultsA total of 933 stroke patients were included. Higher choline and betaine levels were generally associated with lower odds of more severe neurological deficit trajectories. Compared with the lowest tertile, the highest choline tertile had adjusted odds ratios (aORs) of 0.68 (95% confidence interval [CI]: 0.44-1.04) for moderate neurological deficits and 0.24 (95% CI: 0.09-0.66) for persistent-severe deficits. Corresponding aORs for betaine were 0.57 (95% CI: 0.37-0.90) and 0.20 (95% CI: 0.08-0.51), respectively. Furthermore, in fully adjusted models, each 1-SD higher log-choline and -betaine was associated with 26% and 28% lower odds of moderate-to-severe neurological deficit. In addition, both choline and betaine improved risk discrimination and reclassification for moderate-to-severe neurological deficit beyond conventional risk factors.
conclusionsOur study found that lower plasma levels of choline and betaine were generally associated with moderate and persistent-severe neurological function trajectories.
trial registrationNCT01840072; registration date: 2013-04-13.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.